A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

NCT02662634 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

BIOLOGICAL: AGS-003-LNG
DRUG: Carboplatin
DRUG: Abraxane
DRUG: Alimta
DRUG: Cisplatin
DRUG: Taxol
RADIATION: Radiation Therapy

Sponsor

GU Research Network, LLC